↓ Skip to main content

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy

Overview of attention for article published in Journal for Immunotherapy of Cancer, May 2019
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (77th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

twitter
17 X users

Citations

dimensions_citation
63 Dimensions

Readers on

mendeley
68 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
Published in
Journal for Immunotherapy of Cancer, May 2019
DOI 10.1186/s40425-019-0600-6
Pubmed ID
Authors

Yixin Zhou, Zuan Lin, Xuanye Zhang, Chen Chen, Hongyun Zhao, Shaodong Hong, Li Zhang

X Demographics

X Demographics

The data shown below were collected from the profiles of 17 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 68 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 8 12%
Student > Master 7 10%
Researcher 7 10%
Student > Doctoral Student 6 9%
Student > Bachelor 5 7%
Other 11 16%
Unknown 24 35%
Readers by discipline Count As %
Medicine and Dentistry 22 32%
Biochemistry, Genetics and Molecular Biology 7 10%
Pharmacology, Toxicology and Pharmaceutical Science 6 9%
Nursing and Health Professions 3 4%
Immunology and Microbiology 1 1%
Other 3 4%
Unknown 26 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 May 2019.
All research outputs
#4,230,658
of 25,385,509 outputs
Outputs from Journal for Immunotherapy of Cancer
#1,118
of 3,424 outputs
Outputs of similar age
#81,633
of 362,900 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#36
of 74 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,424 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 362,900 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 74 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.